PortalPublikationenExpanding TAVI to Low and Intermediate Risk Patients

Expanding TAVI to Low and Intermediate Risk Patients

Standard

Expanding TAVI to Low and Intermediate Risk Patients. / Voigtländer, Lisa; Seiffert, Moritz.

in: FRONT CARDIOVASC MED, Jahrgang 5, 2018, S. 92.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Voigtländer, L & Seiffert, M 2018, 'Expanding TAVI to Low and Intermediate Risk Patients', FRONT CARDIOVASC MED, Jg. 5, S. 92. https://doi.org/10.3389/fcvm.2018.00092

APA

Voigtländer, L., & Seiffert, M. (2018). Expanding TAVI to Low and Intermediate Risk Patients. FRONT CARDIOVASC MED, 5, 92. https://doi.org/10.3389/fcvm.2018.00092

Vancouver

Voigtländer L, Seiffert M. Expanding TAVI to Low and Intermediate Risk Patients. FRONT CARDIOVASC MED. 2018;5:92. https://doi.org/10.3389/fcvm.2018.00092

Bibtex

@article{234684356cc04bc09c1f4fa88a59de21,
title = "Expanding TAVI to Low and Intermediate Risk Patients",
abstract = "TAVI has become the standard treatment in patients at increased surgical risk and is increasingly being performed in patients at intermediate to low surgical risk. While non-inferiority has been demonstrated in intermediate risk patients, several challenges-particularly with regard to valve durability-need to be addressed before expansion to lower risk and younger patients can be recommended on a broad basis. Current trends, trials results, and remaining challenges are summarized and discussed in the light of updated treatment guidelines.",
author = "Lisa Voigtl{\"a}nder and Moritz Seiffert",
year = "2018",
doi = "10.3389/fcvm.2018.00092",
language = "English",
volume = "5",
pages = "92",
journal = "FRONT CARDIOVASC MED",
issn = "2297-055X",
publisher = "Frontiers Media S. A.",

}

RIS

TY - JOUR

T1 - Expanding TAVI to Low and Intermediate Risk Patients

AU - Voigtländer, Lisa

AU - Seiffert, Moritz

PY - 2018

Y1 - 2018

N2 - TAVI has become the standard treatment in patients at increased surgical risk and is increasingly being performed in patients at intermediate to low surgical risk. While non-inferiority has been demonstrated in intermediate risk patients, several challenges-particularly with regard to valve durability-need to be addressed before expansion to lower risk and younger patients can be recommended on a broad basis. Current trends, trials results, and remaining challenges are summarized and discussed in the light of updated treatment guidelines.

AB - TAVI has become the standard treatment in patients at increased surgical risk and is increasingly being performed in patients at intermediate to low surgical risk. While non-inferiority has been demonstrated in intermediate risk patients, several challenges-particularly with regard to valve durability-need to be addressed before expansion to lower risk and younger patients can be recommended on a broad basis. Current trends, trials results, and remaining challenges are summarized and discussed in the light of updated treatment guidelines.

U2 - 10.3389/fcvm.2018.00092

DO - 10.3389/fcvm.2018.00092

M3 - SCORING: Review article

C2 - 30050909

VL - 5

SP - 92

JO - FRONT CARDIOVASC MED

JF - FRONT CARDIOVASC MED

SN - 2297-055X

ER -